—— About us ——

    Ocbt Biomedical Technology (Suzhou) Co., Ltd. was established in Suzhou in November 2010. It is a Sino foreign joint venture dedicated to the development of high-tech biomedical specialty in the diagnosis and treatment of urinary system diseases. The scientific research team of the company is led by well-known Chinese and foreign scientists and a number of Chinese and foreign experts who have been active in the field of international cancer research for a long time.
    The first phase of the company's products are mainly new, non-invasive, humoral based prostatitis detection reagents, while developing tumor specific detection platform and reagents.
    Enko has global original products: prostate body leakage protein detection kit (ELISA) and prostate corpuscle leakage protein detection kit (colloidal gold method). With global originality, it fills the gap in the global chronic prostatitis in vitro diagnosis. The kit is simple and reliable, and can be used for general clinical reference and general survey of young and middle-aged men.
At the same time, another global original product, the kit for early diagnosis and prognosis of prostate cancer based on urine delta catenin level, is also in the stage of clinical trial and registration application.
    In order to accelerate the application of innovative technology in clinical application, oncology will continue to expand GMP base and build it into a new biomedical center. The tenet of oncology medicine is to take the interests of patients as the center, quickly push the products into clinical practice, early screening, early diagnosis, early treatment, and improve the quality of life of patients.

Office R & D building

Production center

                                                                                                                                                                Office R & D building